Globally, breast cancer is the leading cause of cancer-related deaths among women, often diagnosed at advanced stages when treatment is less effective and more expensive. In India, approximately half of breast cancer patients succumb to the disease within two to five years of diagnosis. Traditional mammography-based screening is not well-suited for developing countries due to its high costs, requirement for skilled operators, lack of portability, and patient discomfort. Furthermore, there is a dearth of effective screening methods for women under 45, who constitute a significant proportion of breast cancer cases in India. Privacy concerns also hinder screening uptake, leading to delayed diagnoses. To improve early detection, reduce mortality rates, and enhance overall outcomes, an affordable, accessible, and automated breast cancer screening solution is urgently required.

Thermalytix, developed by Niramai Health Analytix, is an AI-powered breast cancer screening tool certified by CDSCO and CE. This radiation-free device is designed to detect cancer at early stages, providing an innovative approach to breast health assessment through automated technology. This portable, affordable, and patient-friendly test uses thermal imaging to identify abnormal cell activity much earlier than palpable lumps, making it suitable for women of all ages and breast densities. Thermalytix analyzes thermal images to detect breast malignancies by identifying abnormal thermal activities linked to higher metabolic activity. The AI-based algorithm examines the temperature distribution on the breast surface, detecting asymmetrical vascular patterns and high-temperature regions indicative of abnormalities. This ensures accurate, automated detection without physical contact, respecting patient privacy. By providing an early and precise diagnosis, Thermalytix enhances breast cancer detection and treatment outcomes.